A drug having code number R 1583, a Swiss company’s product, is going to mark a significant improvement in the history of medical Diabetes.
The drug belongs to a new type group called GLP-1 analogues which aims in treating type 2 diabetes. The structure of molecule is similar to that of natural human hormone GLP-1, which causes pancreas to produce more insulin while simultaneously discouraging the liver from producing sugar.
Other than R 1583 only one drug comes in the class of GLP-1. That is Eli Lilly’s (LLY) Byetta which is already in the market.
The data on this drug is believed to be a winner in comparison of data on new drugs by companies such as Sanofi-Aventis SA (SNY), Novo Nordisk A/S.
“Roche’s product achieved good results in terms of lowering HbA1c, a key indicator for sustainable blood sugar reduction, and patients taking it lost weight,” says Nawrath, analyst at Zuercher Kantonalbank. Moreover Denise Anderson, pharmaceutical analyst at Kepler Landesbanki in Zurich, says that “Roche/Ipsen’s product appears to be significantly more user- friendly in our view and we therefore forecast that the drug could be best in class.”
Moreover this new version of Byetta will require only once-a-week injections, whereas other drugs like Liraglutide needs once a day injections.
As Roche acquires the marketing rights of this drug from a French company Ipsen (1025915.FR), he will soon move this drug to the clinical phase of III.
Thus we believe that this drug is going to bring some promising outcome.
Source: CNN Money.com
Filed under Blood Sugar Testing, Diabetes, Diabetes Drug | Tags: Byetta, GLP-1, HbA1c, Ipsen (1025915.FR), Liraglutide, Lost, Novo Nordisk A/S, R 1583, Sanofi-Aventis SA, SNY, type 2 diabetes | Comment Below